Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer.

Germline pathogenic variants, most often in Lynch syndrome genes, CHEK2, ATM and BRCA2, associated with more aggressive MRI findings and more frequent pathologic upgrading after prostatectomy

This single-center retrospective case-control study compared 62 patients with prostate cancer carrying at least one germline pathogenic variant (Lynch syndrome 17.7%, CHEK2 21.0%, ATM 17.7%, BRCA2 19.4%) with 246 consecutive controls, all with an MRI at diagnosis. Median age at diagnosis was not significantly younger in carriers (65 versus 67 years, p = 0.05) and the proportion of positive MRI (PI-RADS ≥ 3) was similar (98% versus 96%). Carriers more often had a PI-RADS 5 score (OR 2.7; CI 1.5-4.9) and grade 3 extra-prostatic extension (OR 3.0; CI 1.5-5.8). After prostatectomy, 37% of carriers were reclassified to a higher-grade group versus 20% of controls (p = 0.046).

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Carriers show signs of aggressiveness on MRI and more frequent upgrading after prostatectomy, which supports the role of imaging in early detection strategies for them. The 62 carriers, however, bring together very different genes (Lynch, CHEK2, ATM, BRCA2): no gene-specific conclusion is possible, and the upgrading threshold (p = 0.046) is barely crossed. The abstract describes imaging and grade features, not survival or detection outcomes.

Analysis by Dr Thibaut Benquey